| Q55092208 | 17β-Estradiol and/or estrogen receptor alpha signaling blocks protein phosphatase 1 mediated ISO induced cardiac hypertrophy. |
| Q37357819 | A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation |
| Q47551370 | AAV-9 mediated phosphatase-1 inhibitor-1 overexpression improves cardiac contractility in unchallenged mice but is deleterious in pressure-overload |
| Q36707489 | AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling |
| Q37874426 | AKAP phosphatase complexes in the heart |
| Q37478226 | Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart |
| Q57159563 | Activation of protein phosphatase 1 by a selective phosphatase disrupting peptide reduces sarcoplasmic reticulum Ca leak in human heart failure |
| Q35061110 | Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts |
| Q28081681 | Adeno-associated virus-mediated gene therapy in cardiovascular disease |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q61807422 | Age-Dependent Protein Expression of Serine/Threonine Phosphatases and Their Inhibitors in the Human Cardiac Atrium |
| Q37239340 | Alterations in ryanodine receptors and related proteins in heart failure |
| Q36401773 | Alterations in the interactome of serine/threonine protein phosphatase type-1 in atrial fibrillation patients. |
| Q36837270 | Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy |
| Q58614496 | Assessment of PKA and PKC inhibitors on force and kinetics of non-failing and failing human myocardium |
| Q37358922 | Beta-adrenergic stimulation and myocardial function in the failing heart |
| Q41775044 | Ca(2+)-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals |
| Q39493909 | Ca2+ cycling and new therapeutic approaches for heart failure |
| Q37601736 | CaMKII Phosphorylation of Na(V)1.5: Novel in Vitro Sites Identified by Mass Spectrometry and Reduced S516 Phosphorylation in Human Heart Failure |
| Q37279355 | CaMKII-induced shift in modal gating explains L-type Ca(2+) current facilitation: a modeling study. |
| Q37915240 | Calcium cycling proteins and their association with heart failure |
| Q34409721 | Cardiac Gene Therapy |
| Q27318604 | Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure |
| Q37965045 | Cardiac gene therapy: from concept to reality |
| Q36260328 | Cardiac-specific deletion of protein phosphatase 1β promotes increased myofilament protein phosphorylation and contractile alterations |
| Q36298960 | Ca²+-regulatory proteins in cardiomyocytes from the right ventricle in children with congenital heart disease |
| Q48773347 | Chronic loss of inhibitor-1 diminishes cardiac RyR2 phosphorylation despite exaggerated CaMKII activity |
| Q36653535 | Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging |
| Q42182103 | Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging |
| Q36923928 | Contractile protein phosphorylation predicts human heart disease phenotypes |
| Q26776182 | Counteracting Protein Kinase Activity in the Heart: The Multiple Roles of Protein Phosphatases |
| Q64930555 | Current Landscape of Heart Failure Gene Therapy. |
| Q34409221 | Defects in T-tubular electrical activity underlie local alterations of calcium release in heart failure |
| Q36194321 | Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy |
| Q41591995 | E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling. |
| Q37522203 | Elucidating the role of reversible protein phosphorylation in sepsis-induced myocardial dysfunction |
| Q42734340 | Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis |
| Q38139729 | Function and regulation of serine/threonine phosphatases in the healthy and diseased heart. |
| Q90590745 | Functions and therapeutic potential of protein phosphatase 1: Insights from mouse genetics |
| Q37783642 | GRK2 as a novel gene therapy target in heart failure. |
| Q91606337 | Gene Therapy for Heart Failure: New Perspectives |
| Q83556143 | Gene therapy for heart failure |
| Q38073152 | Gene therapy for heart failure: where do we stand? |
| Q36953151 | Gene therapy for the treatment of heart failure: promise postponed |
| Q36944623 | Gene therapy in heart failure |
| Q27022444 | Gene therapy targets in heart failure: the path to translation |
| Q34059173 | Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy |
| Q37026733 | Global comparison of phosphoproteins in human and rodent hearts: implications for translational studies of myosin light chain and troponin phosphorylations |
| Q33605156 | Heart failure management: the present and the future |
| Q28482901 | Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling |
| Q38186583 | Heart failure-specific changes in protein kinase signalling. |
| Q36399731 | Human G109E-inhibitor-1 impairs cardiac function and promotes arrhythmias |
| Q42906788 | Identification of a protein phosphatase-1/phospholamban complex that is regulated by cAMP-dependent phosphorylation |
| Q88412812 | Impaired Ca2+ cycling of nonischemic myocytes contributes to sarcomere dysfunction early after myocardial infarction |
| Q36968418 | Impaired cardiac contractility in mice lacking both the AE3 Cl-/HCO3- exchanger and the NKCC1 Na+-K+-2Cl- cotransporter: effects on Ca2+ handling and protein phosphatases |
| Q80300392 | Independent FHC-related cardiac troponin T mutations exhibit specific alterations in myocellular contractility and calcium kinetics |
| Q37364808 | Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. |
| Q41959948 | Inhibition of serine/threonine protein phosphatase PP1 protects cardiomyocytes from tunicamycin-induced apoptosis and I/R through the upregulation of p-eIF2α. |
| Q36995149 | Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality |
| Q36502630 | Integration of calcium with the signaling network in cardiac myocytes. |
| Q50545091 | Isoform-specific roles of protein phosphatase 1 catalytic subunits in sarcoplasmic reticulum-mediated Ca2+ cycling |
| Q46911383 | Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance |
| Q36359887 | Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia. |
| Q39310132 | Mechanisms of SR calcium release in healthy and failing human hearts |
| Q26823061 | Model-specific selection of molecular targets for heart failure gene therapy |
| Q30318574 | Modulation of cardiac contractility by serine/threonine protein phosphatase type 5 |
| Q24337593 | Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome |
| Q36526222 | Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart |
| Q28265749 | Molecular targets in heart failure gene therapy: current controversies and translational perspectives |
| Q37738659 | Neuregulin signaling and heart failure |
| Q28295209 | Neuregulin-1/ErbB Signaling and Chronic Heart Failure |
| Q80915724 | Overexpression of junctate induces cardiac hypertrophy and arrhythmia via altered calcium handling |
| Q42578799 | Phosphatase-1-inhibitor-1: amplifier or attenuator of catecholaminergic stress? |
| Q35032742 | Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend |
| Q34289975 | Phosphoprotein abundance changes in hypertensive cardiac remodeling |
| Q35158657 | Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C. |
| Q36676340 | Phosphorylation state-dependent interaction between AKAP7δ/γ and phospholamban increases phospholamban phosphorylation |
| Q36497159 | Potential of gene therapy as a treatment for heart failure |
| Q39356341 | Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases |
| Q37219497 | Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis |
| Q41928538 | Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure. |
| Q28253877 | Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardium |
| Q52316870 | Rearrangement of the Protein Phosphatase 1 Interactome During Heart Failure Progression. |
| Q37822275 | Refilling Intracellular Calcium Stores |
| Q38963034 | Regulating the regulator: Insights into the cardiac protein phosphatase 1 interactome |
| Q34757960 | Rescuing the failing heart by targeted gene transfer |
| Q37145537 | Role of PP1 in the regulation of Ca cycling in cardiac physiology and pathophysiology |
| Q38820202 | Role of protein phosphatase inhibitor-1 in cardiac beta adrenergic pathway |
| Q37276968 | Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology |
| Q37248371 | Ryanodine receptor-mediated arrhythmias and sudden cardiac death. |
| Q36476041 | SERCA2a in heart failure: role and therapeutic prospects |
| Q38109648 | SERCA2a: a prime target for modulation of cardiac contractility during heart failure |
| Q37676218 | Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure |
| Q34201068 | Sex-dependent, zinc-induced dephosphorylation of phospholamban by tissue-nonspecific alkaline phosphatase in the cardiac sarcomere |
| Q41847102 | Should we treat heart failure with phosphatase inhibitors? Better to start at the end. |
| Q42778625 | Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling |
| Q59360573 | Successful overexpression of wild-type inhibitor-2 of PP1 in cardiovascular cells |
| Q45858131 | Synergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca2+ -ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cells |
| Q37089726 | Tackling heart failure in the twenty-first century |
| Q37878086 | Targeted gene therapy for the treatment of heart failure |
| Q35763705 | Targeting cardiomyocyte Ca2+ homeostasis in heart failure |
| Q37229784 | The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases |
| Q34051035 | The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure |
| Q34700997 | The large isoforms of A-kinase anchoring protein 18 mediate the phosphorylation of inhibitor-1 by protein kinase A and the inhibition of protein phosphatase 1 activity. |
| Q38813273 | The neglected messengers: Control of cardiac myofilaments by protein phosphatases. |
| Q45353933 | Up-regulation of micro-RNA765 in human failing hearts is associated with post-transcriptional regulation of protein phosphatase inhibitor-1 and depressed contractility |
| Q79846175 | [Reverse remodeling of the intracellular Ca(2+)-homeostasis: new concepts of pathophysiology and therapy of heart failure] |
| Q34976170 | p38α regulates SERCA2a function. |